Milton L Pressler

US Patent:

6645959, Nov 11, 2003

Filed:

Apr 19, 2002

Appl. No.:

10/111274

Inventors:

Rebecca Guggemos Bakker-Arkema - Ann Arbor MI
Milton Lethan Pressler - Saline MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3155

US Classification:

514215, 514200, 514481, 514471

Abstract:

This invention is a method for preventing or treating postoperative ileus comprising administering a vasopressin antagonist such as a compound of Formula (1), where R , R , and R include hydrogen, halo, alkyl, and alkoxy; R and R are hydrogen or alkyl; R is hydrogen, phenyl, or substituted phenyl, and pharmaceutically acceptable salts thereof.

US Patent:

6740648, May 25, 2004

Filed:

Oct 3, 2001

Appl. No.:

09/970211

Inventors:

Maha Ghazzi - Ann Arbor MI
Milton Lethan Pressler - Saline MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3155

US Classification:

514217

Abstract:

Disclosed is a method for treating pulmonary hypertension using a vasopressin antagonist.

US Patent:

7192951, Mar 20, 2007

Filed:

Jun 16, 2005

Appl. No.:

11/154909

Inventors:

Rebecca Guggemos Bakker-Arkema - Ann Arbor MI, US
Milton Lethan Pressler - Saline MI, US

Assignee:

Astellas Pharma Inc.

International Classification:

A61K 31/55
A61K 31/34

US Classification:

514215, 514471

Abstract:

Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formula.

US Patent:

20020115661, Aug 22, 2002

Filed:

Sep 7, 2001

Appl. No.:

09/949204

Inventors:

Laurence Keller - Ann Arbor MI, US
Milton Pressler - Saline MI, US

International Classification:

A61K031/5415

US Classification:

514/226500

Abstract:

Chronic obstructive pulmonary disease is treated with a selective ETreceptor antagonist such as 4-(7-ethyl-1,3-benxodioxol-5-yl)-2-[2-trifluoromethyl) phenyl]-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide or a pharmaceutically acceptable salt thereof.

US Patent:

20030008860, Jan 9, 2003

Filed:

May 9, 2002

Appl. No.:

10/129892

Inventors:

Rebecca Bakker-Arkema - Ann Arbor MI, US
Milton Pressler - Saline MI, US

International Classification:

A61K031/55
A61K031/34

US Classification:

514/215000, 514/471000

Abstract:

Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formula (I) wherein R and Rare hydrogen or lower alkyl; R, R, and Rare hydrogen, halo, alkyl, alkoxy, and amino; and Ris hydrogen or phenyl, and a pharmaceutically acceptable salt thereof

US Patent:

20030103983, Jun 5, 2003

Filed:

May 9, 2002

Appl. No.:

10/130168

Inventors:

Milton Pressler - Saline MI, US

International Classification:

A61K039/395

US Classification:

424/176100

Abstract:

Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.

US Patent:

20040176354, Sep 9, 2004

Filed:

Mar 12, 2004

Appl. No.:

10/799415

Inventors:

Rebecca Bakker-Arkema - Ann Arbor MI, US
Milton Pressler - Saline MI, US

International Classification:

A61K031/55

US Classification:

514/215000

Abstract:

Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formula wherein R and Rare hydrogen or lower alkyl; R, R, and Rare hydrogen, halo, alkyl, alkoxy, and amino; and Ris hydrogen or phenyl, and a pharmaceutically acceptable salt thereof.

US Patent:

20050191278, Sep 1, 2005

Filed:

Apr 12, 2005

Appl. No.:

11/104126

Inventors:

Milton Pressler - Saline MI, US
Donald Black - Princeton NJ, US
Paul Fischer - North Potomac MD, US
Henrik Rasmussen - Arnold MD, US
Margaret Samyn - Gainesville FL, US
Grant Yonehiro - San Mateo CA, US

Assignee:

GenVec, Inc. - Gaithersburg MD
Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K048/00
A61M031/00

US Classification:

424093200, 604500000

Abstract:

The invention provides a method of treating coronary artery disease in a human patient comprising directly injecting into an ischemic cardiac muscle, via multiple injections to different points of the cardiac muscle, a dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding an angiogenic peptide operably linked to a promoter, whereby the coronary artery disease is treated.